Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clovis Transitions To Commercial Stage On Rubraca Approval

Executive Summary

FDA granted accelerated approval to PARP inhibitor Rubraca for treatment with BRCA-mutation positive ovarian cancer patients treated with two or more chemotherapies.

Advertisement

Related Content

Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations
Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space
Mateon's CA4P Disappoints At Second Interim Analysis, More Data Awaited
The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca
Q&A: FDA Dx Reviewer's Tips For Next-Gen Sequencing Sponsors
US FDA Shows Relaxed Approach On Personalized Medicine In Zejula Approval
AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza
Medivation Hopes Details On Talazoparib Will Inspire Heightened M&A Bidding
Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors
Clovis Plans Rucaparib Commercial Launch, After Abandoning Rociletinib

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel